Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

The path to destruction for D-type cyclin proteins

The molecular mechanism governing the destruction of key cell-cycle proteins, D-type cyclins, has been elucidated. This mechanism might underlie the lack of response of some human tumours to an inhibitor treatment.
  1. Charupong Saengboonmee

    1. Charupong Saengboonmee is in the Department of Cancer Biology, Dana-Farber Cancer Institute, and in the Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02215, USA; and in the Department of Biochemistry, Faculty of Medicine and Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Piotr Sicinski

    1. Piotr Sicinski is in the Department of Cancer Biology, Dana-Farber Cancer Institute, and in the Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Proteins called D-type cyclins (cyclin D1, D2 and D3) are key components of the core cell-cycle engine, which drives cellular division. Writing in Nature, Simoneschi et al.1, Chaikovsky et al.2 and Maiani et al.3 provide the long-sought answer to how D-type cyclins are normally degraded.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 592, 690-691 (2021)

doi: https://doi.org/10.1038/d41586-021-00889-0

References

  1. Simoneschi, D. et al. Nature 592, 789–793 (2021).

    Article  Google Scholar 

  2. Chaikovsky, A. C. et al. Nature 592, 794–798 (2021).

    Article  Google Scholar 

  3. Maiani, E. et al. Nature 592, 799–804 (2021).

    Article  Google Scholar 

  4. Otto, T. & Sicinski, P. Nature Rev. Cancer 17, 93–115 (2017).

    Article  PubMed  Google Scholar 

  5. Sherr, C. J., Beach, D. & Shapiro, G. I. Cancer Discov. 6, 353–367 (2016).

    Article  PubMed  Google Scholar 

  6. Lin, D. I. et al. Mol. Cell 24, 355–366 (2006).

    Article  PubMed  Google Scholar 

  7. Chen, S.-H. et al. EMBO J. 37, e97508 (2018).

    PubMed  Google Scholar 

  8. Petroski, M. D. & Deshaies, R. J. Nature Rev. Mol. Cell Biol. 6, 9–20 (2005).

    Article  PubMed  Google Scholar 

  9. Qie, S. & Diehl, J. A. J. Mol. Med. 94, 1313–1326 (2016).

    Article  PubMed  Google Scholar 

  10. Kanie, T. et al. Mol. Cell Biol. 32, 590–605 (2012).

    Article  PubMed  Google Scholar 

  11. Cianfanelli, V., Nazio, F. & Cecconi, F. Mol. Cell Oncol. 2, e970059 (2015).

    Article  PubMed  Google Scholar 

  12. Fimia, G. M. et al. Nature 447, 1121–1125 (2007).

    Article  PubMed  Google Scholar 

  13. Jin, J., Arias, E. E., Chen, J., Harper, J. W. & Walter, J. C. Mol. Cell 23, 709–721 (2006).

    Article  PubMed  Google Scholar 

  14. Cianfanelli, V. et al. Nature Cell Biol. 17, 20–30 (2015).

    Article  PubMed  Google Scholar 

  15. Bretones, G., Delgado, M. D. & Leon, J. Biochim. Biophys. Acta 1849, 506–516 (2015).

    Article  PubMed  Google Scholar 

  16. Finn, R. S. et al. Lancet Oncol. 16, 25–35 (2015).

    Article  PubMed  Google Scholar 

  17. Finn, R. S. et al. Clin. Cancer Res. 26, 110–121 (2020).

    Article  PubMed  Google Scholar 

  18. Li, Z. et al. Cancer Cell 34, 893–905 (2018).

    Article  PubMed  Google Scholar 

  19. Turner, N. C. et al. J. Clin. Oncol. 37, 1169–1178 (2019).

    Article  PubMed  Google Scholar 

  20. Herrera-Abreu, M. T. et al. Cancer Res. 76, 2301–2313 (2016).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

P.S. has been a consultant at Novartis, Genovis, Guidepoint, The Planning Shop, ORIC Pharmaceuticals, Syros, Cedilla Therapeutics and Exo Therapeutics. His laboratory has received research funding from Novartis.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links